All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Thrombotic events in MPN: Primary prophylaxis to avoid the first arterial and venous events

Jul 26, 2022
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in myeloproliferative neoplasms.

During the EHA 2022 Congress, the MPN Hub was pleased to speak to Tiziano Barbui, Papa Giovanni XXIII Hospital, Bergamo, IT. We asked, Thrombotic events in MPN: What is the primary prophylaxis used to avoid the first arterial and venous events.

Thrombotic events in MPN: Primary prophylaxis to avoid the first arterial and venous events

Barbui begins by talking about managing thrombotic risk, and how primary prophylaxis can affect the thrombotic risk. Barbui also discusses drugs used to manage thrombosis, including aspirin, interferons, hydroxyurea, and ruxolitinib.